Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
缺氧激活前药与（缺乏）临床进展：III期临床试验中基于缺氧生物标志物进行患者选择的必要性
期刊:Clinical and Translational Radiation Oncology
影响因子:2.7
doi:10.1016/j.ctro.2019.01.005
Spiegelberg, Linda; Houben, Ruud; Niemans, Raymon; de Ruysscher, Dirk; Yaromina, Ala; Theys, Jan; Guise, Christopher P; Smaill, Jeffrey B; Patterson, Adam V; Lambin, Philippe; Dubois, Ludwig J
